Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Giammarco Surico, Antonio Febbraro et al.|Breast Cancer Research and Treatment|2017Cited by 12
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experienceE.S. Lutrino, Saverio Cinieri, Laura Orlando et al.|Tumori Journal|2019Cited by 6
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Elena Cazzaniga, Valter Torri, Claudio Verusio et al.|Oncotarget|2018Cited by 4
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacy—An Italian multicenter experience.Stefania Eufemia Lutrino, Saverio Cinieri, Laura Orlando et al.|Journal of Clinical Oncology|2016Cited by 3
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA StudiesMarina Elena Cazzaniga, P. Pronzato, Claudio Verusio et al.|Breast Care|2019Cited by 1